Suspended

Pharmacokinetic Analysis of Marine Active in Healthy Men for Hyperuricemia Management

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Pathologic Processes

+ Pathological Conditions, Signs and Symptoms

+ Hyperuricemia

From 20 to 35 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 1
Interventional
See protocol details

Summary

Principal SponsorChina Medical University Hospital
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Hyperuricemia, a common metabolic disorder, can lead to gout, a condition characterized by painful joints. It occurs when there's too much uric acid in the body, either due to decreased removal or increased production. While diet control can help manage uric acid levels, it's often not sufficient. This is where Marine Active, a dipeptide extract from Bonito and Tuna, comes into play. Developed by the Yaizu Suisankagaku Industry Company, Marine Active has shown potential in reducing uric acid levels and offering anti-fatigue benefits in animal trials and early human studies. This research aims to understand how Marine Active can help manage hyperuricemia, particularly in healthy men who do not have gout but have high uric acid levels, as it's important to find effective ways to manage this condition and potentially prevent gout. In this study, healthy men will take 1 gram of Marine Active. The study is designed as a randomized, double-blind clinical trial, meaning neither the participants nor the researchers will know who is receiving Marine Active or a placebo. The main goal is to analyze the pharmacokinetics of Anserine, a component of Marine Active, by taking blood samples. This will help understand how the body absorbs, distributes, metabolizes, and excretes Anserine. By conducting this study, researchers hope to gain insights into the potential benefits and risks of Marine Active, paving the way for improved management of hyperuricemia.

Official TitlePharmacokinetic Study of Marine Active in Health Men
NCT00207974
Principal SponsorChina Medical University Hospital
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Male

Biological sex of participants that are eligible to enroll.

From 20 to 35 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Pathologic ProcessesPathological Conditions, Signs and SymptomsHyperuricemia

Criteria

Inclusion Criteria: -Male volunteers, age between 20 to 35 years Exclusion Criteria: * Chronic medical history * Significant liver or renal dysfunction, * Have been administrated by any drug within 2 weeks before the initiation of study.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

China Medical University Hospital

Taichung, TaiwanOpen China Medical University Hospital in Google Maps
SuspendedOne Study Center